HONG KONG SAR –
Media OutReach – 30 May 2022 – A research team led by Hong Kong Baptist University (HKBU) has found that a proteolytic enzyme called
membrane-type 1 matrix metalloproteinase (MT1-MMP) plays an important role in the regulatory mechanism of fullness, or satiety, and it could serve as a promising potential drug target for the management of obesity.
Dr Xavier Wong Hoi-leong, Assistant Professor of the Teaching and Research Division of the School of Chinese Medicine (left), and Professor Bian Zhaoxiang, Director of the Clinical Division of the School of Chinese Medicine and Tsang Shiu Tim Endowed Chair of Chinese Medicine Clinical Studies at HKBU (right), identified a proteolytic enzyme called MT1-MMP which could serve as a promising potential drug target for the management of obesity.
The research findings were published in the internationally-renowned scientific journal
Nature Metabolism. The study has also been featured as a research highlight in multiple high-impact journals, including
Nature Reviews Endocrinology,
Nature Metabolism and
Half of Hong Kong’s population obese or overweight
Being overweight, especially to the extent of obesity, exposes people to a higher risk of life-threatening diseases such as cardiovascular diseases, diabetes, and cancer. According to the Population Health Survey conducted in 2014/15 by the Department of Health, about 30% of people in Hong Kong aged 15 to 84 were obese, and another 20% were overweight.
The most effective way to tackle obesity is to reduce food consumption, but obese people often encounter difficulties in regulating their dietary habits as they lose their sense of satiety. Identifying a factor that specifically controls body weight, and investigating how it regulates our sense of satiety, is crucial for the development of therapeutic approaches for obesity.
Identification of new regulator of satiety signals
A research team led by Dr Xavier Wong Hoi-leong, Assistant Professor of the Teaching and Research Division of the School of Chinese Medicine (SCM), and Professor Bian Zhaoxiang, Director of the Clinical Division of SCM and Tsang Shiu Tim Endowed Chair of Chinese Medicine Clinical Studies at HKBU, identified a proteolytic enzyme called
MT1-MMP which regulates the mechanism of issuing satiety signals in the human brain.
Growth and differentiation factor 15 (GDF15) is a hormone that sends out satiety signals by binding with the neuron receptor in the hindbrain called
GDNF-family receptor α-like (GFRAL). Mediation of GFRAL can therefore affect the ability of GDF15 to send satiety signals, and thus help regulate food intake. From this starting point, the research team conducted a series of experiments to investigate the mediation effects of MT1-MMP on GFRAL.
Depletion of MT1-MMP reduces obesity
The research team generated an obesity mouse model by feeding a fat-rich diet to a group of transgenic mice with a depletion of MT1-MMP in their satiety neurons, as well as a control group of ordinary mice. After 16 weeks, the mice with depleted MT1-MMP ate 10% less food, gained 50% less weight, and exhibited reduced glucose and plasma insulin levels compared to the control group. The results show that
depletion of MT1-MMP protects mice from obesity induced by a high-fat diet.
Following analysis with western blots, a widely used analytical technique that can detect specific proteins, the research team also found that the obese mice displayed an increased activity of MT1-MMP in the Area Postrema and Nucleus of the Solitary Tract, the brain regions involved in appetite and weight regulation. The finding suggests that
increased MT1-MMP activity in the brain of obese mice could be a risk factor causing sustained weight gain.
To understand the mechanism by which MT1-MMP suppresses GDF15 satiety signalling, the research team conducted a series of molecular biology experiments involving animal models and cell culture. The results show that in cells with active MT1-MMP, a significant reduction of GFRAL and thus GDF15 signalling were observed. It could be explained by
MT1-MMP clipping GFRAL from the surface of the brain neurons, which blocks GDF15 from binding to GFRAL and thus reduces the number of satiety signals. This in turn keeps the neurons from transmitting the satiety signals sent by GDF15.
therapeutic target for obesity
The researchers also explored the therapeutic potential of targeting MT1-MMP for obesity management, in particular through pharmacological inhibition of its activity
in vivo. With the application of a specific neutralising antibody that inhibits MT1-MMP, significant improvements in metabolic parameters including food intake, glucose tolerance and body weight in obese mice were observed. The results suggest that
MT1-MMP is a potential therapeutic target that could be used in the development of innovative drug treatments for obesity.
Dr Wong said: “The research findings have established the role played by MT1-MMP in regulating satiety, and they have provided preliminary indications that the proteolytic enzyme is a promising target for the treatment of obesity. Pharmacological inhibition of MT1-MMP could be a viable strategy for the development of effective pharmacotherapy for the treatment of obesity.”
Apart from researchers from HKBU, the research team included scientists from The University of Hong Kong, The Chinese University of Hong Kong, the University of Texas Health Science Center at Houston, and the University of Helsinki.